Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data DataMeds AI, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
18.1
23.3
Cost of revenue
16.4
29.8
Gross profit
1.77
-6.43
Selling and marketing
1.22
General and administrative
2.88
6.8
70.3
Operating expenses
2.88
7.91
87.3
Operating income
-2.88
-6.15
-93.7
Interest expense
0.02
0.83
4.58
Other non-operating income
-0.02
-0.71
-7.53
Pre-tax income
-2.9
-6.86
-101
Net income
-2.9
-6.86
-101
EBITDA
-5.03
-90.5
EPS, basic
-0.06
-0.15
-1.43
EPS, diluted
-0.06
-0.15
-1.43
Shares, basic (weighted)
44.7
47.3
71
Shares, diluted (weighted)
44.7
47.3
71
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
0
1.03
0.04
Receivables
1.14
Inventory
9.52
1.64
Other current assets
0
Total current assets
0.34
15.2
2.82
Property, plant and equipment
0.39
0.23
Lease right-of-use assets
1.53
0.97
Goodwill
16.2
14.2
Intangible assets
1.62
2.5
Other non-current assets
1.44
Total assets
0.34
57.3
30.5
Short-term debt
0.35
11.9
10.9
Total current liabilities
2.89
38
29.8
Long-term debt
11.5
12.6
Lease liabilities
1.1
0.53
Total liabilities
3.24
50.6
42.9
Total debt
0.35
23.4
23.5
Paid-in capital
-0
16.5
98.6
Retained earnings
-2.9
-9.76
-111
Shareholders' equity
-2.9
6.73
-12.4
Total equity
-2.9
6.73
-12.4
Total liabilities and equity
0.34
57.3
30.5
Shares outstanding
44.7
51.1
2.03
Cash flow statement
FY2024
FY2024
FY2025
Net income
-2.9
-6.86
-101
Depreciation and amortization
1.11
3.21
Stock-based compensation
1.08
54.8
Change in receivables
-0.04
0.8
Change in inventory
-0.07
1.89
Change in payables
1.03
-0.88
2.2
Cash from operations
-0.35
-1.22
-10.9
Cash from investing
0.47
-0.88
Stock issued
0.01
Cash from financing
0.35
1.78
10.8
Net change in cash
0
1.03
-0.99
Interest paid
0.33
3.11
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.11 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
-90.6%
Gross profit / revenue.
Operating margin
-875.7%
Operating income / revenue.
EBITDA margin
-846.8%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-1,100.0%
Pre-tax income / revenue.
Net margin
-1,100.0%
Net income / revenue.
Operating cash flow margin
-171.2%
Cash from operations / revenue.
Return on assets (ROA)
-269.5%
Net income / average total assets.
Return on invested capital (ROIC)
-563.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue
356.9%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
28.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
28.7%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
-463.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-284.8%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-46.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
50.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.14x
Current assets / current liabilities.
Quick ratio
0.09x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.06x
(Cash + short-term investments) / current liabilities.
Debt / assets
97.1%
Total debt / total assets.
Liabilities / assets
159.5%
Total liabilities / total assets.
Net debt
$29.3M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.12
Revenue / diluted weighted shares.
Operating cash flow per share
-$5.34
Cash from operations / diluted weighted shares.
Book value per share
-$6.88
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.14x
Market cap / revenue.
EV/Sales
4.79x
Enterprise value / revenue.
Earnings yield
-969.2%
Net income / market cap (the inverse of P/E).
What was DataMeds AI, Inc.'s revenue in fiscal 2025?
DataMeds AI, Inc. reported revenue of $23.3M for fiscal 2025, 28.7% higher than the year before.
Was DataMeds AI, Inc. profitable in fiscal 2025?
No. It reported a net loss of $101.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.